Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane

Retina

Volumn 18, Issue 4, 1998, Pages 322-329

  Olsen, Timothy W ^a,b   Sternberg Jr , Paul ^a   Capone Jr , Antonio ^a   Martin, Daniel F ^a   Lim, Jennifer I ^c   Grossniklaus, Hans E ^a   Aaberg Sr , Thomas M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Autologous cryoprecipitate; Bovine thrombin; Fibrin sealants; Macular hole; Pars plana vitrectomy

Indexed keywords

FIBRINOGEN; THROMBIN; TISSUE ADHESIVE;

ADULT; AGED; ARTICLE; CILIARY DISK; CONTRAST SENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPLASIA; HYPOPYON; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA HOLE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0032472019     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-199807000-00005     Document Type: Article

References (25)

1. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol 1991;109: 654-659.
2. Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD. Vitreous surgery for macular holes. Ophthalmology 1993;100:1671-1676.
3. Freeman WR, Azen SP, Kim JW, Elhaig W, Mishell DR, Bailey I. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes - results of a multicentered randomized clinical trial. Arch Ophthalmol 1997;115:11-21.
4. Ryan EH Jr., Gilbert HD. Results of surgical treatment of recent-onset full-thickness idiopathic macular holes. Arch Ophthalmol 1994;112:1545-1553.
5. Ogino N. Results of macular hole surgery (in Japanese). Nippon Ganka Gakkai Zasshi 1995;99:938-944.
6. Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology 1992;99:1162-1172; Discussion, 1173.
7. Tilanus MA, Deutman AF. Full-thickness macular holes treated with vitrectomy and tissue glue. Int Ophthalmol 1994; 18:355-358.
8. Gaudric A, Paques M, Massin PG, et al. Use of autologous platelet concentrate in full-thickness macular hole surgery: results of a multicenter, double-blind randomized trial. Presented at the annual meeting of the American Academy of Ophthalmology, San Francisco, CA; October 27, 1997:143.
9. Lansing MB, Glaser BM, Liss H, et al. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 1993;100:868-871; Discussion, 871-872.
10. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. Retina 1993;13:296-301.
11. Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology 1995;102:263-271.
12. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995;233:549-554.
13. Korobelnik JF, Hannouche D, Belayachi N, Branger M, Guez JE, Hoang-Xuan T. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Ophthalmology 1996;103:590-594.
14. Alving BM, Weinstein MJ, Finlayson JS, Menitove JE, Fratantoni JC. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion 1995;35:783-790.
15. Yoon HS, Brooks HL, Jr., Capone A, Jr., Grossniklaus HE. Ultrastructural features of tissue removed during idiopathic macular hole surgery. Am J Ophthalmol 1996;122:67-75.
16. Eckardt C, Eckardt U, Groos S, Luciano L, Reale E. Removal of the internal limiting membrane in macular holes. Clinical and morphological findings. Ophthalmologe 1997;94:545-551.
17. Gass JD. Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol 1988;106:629-639.
18. Rubin JS, Thompson JT, Sjaarda RN, Pappas SS, Jr., Glaser BM. Efficacy of fluid-air exchange during pars plana vitrectomy. Retina 1995;15:291-294.
19. Green WR. Retina. In: Spencer WH, ed. Retina. Philadelphia: W.B. Saunders, 1985:589-1291.
20. Madreperla SA, Geiger GL, Funata M, de la Cruz Z, Green WR. Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology 1994;101:682-686.
21. Hackett SF, Singer JH, Leschey KH, Campochiaro PA. Thrombin is a stimulator of retinal pigment epithelial cell proliferation. Exp Eye Res 1991;53:95-100.
22. Olsen TW, Sternberg P, Martin DF, Capone A, Jr., Lim JI, Aaberg TM. Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. Am J Ophthalmol 1996; 121:575-577.
23. Cohen SM, Hammer ME, Grizzard WS. Endophthalmitis after pars plana vitrectomy with or without autologous blood products for macular hole. Ophthalmology 1996;103:161.
24. Fekrat S, Wendel RT, de la Cruz Z, Green WR. Clinicopathologic correlation of an epiretinal membrane associated with a recurrent macular hole. Retina 1995;15:53-57.
25. Vine AK, Johnson MW. Thrombin in the management of full thickness macular holes. Retina 1996;16:474-478.